Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
An Austin-based company that’s developing the blood sugar-regulating hormone glucagon, as opposed to insulin, is in the midst of a decent-sized Series B deal.
Xeris Pharmaceuticals has raised $7.2 million in Series B funding, according to a regulatory filing, with an aim to raise $14.8 million total in the round. Calls to the company to determine what this funding will be used for have yet to be returned – but it’s in the midst of a couple of Phase 2 trials. Xeris has a few programs in the works that center on diabetes, epilepsy and hyperinsulinism.
http://medcitynews.com/2014/09/xeris-developing-glucagon-product-diabetes-control-raises-7-2m/
Xeris Pharmaceuticals has raised $7.2 million in Series B funding, according to a regulatory filing, with an aim to raise $14.8 million total in the round. Calls to the company to determine what this funding will be used for have yet to be returned – but it’s in the midst of a couple of Phase 2 trials. Xeris has a few programs in the works that center on diabetes, epilepsy and hyperinsulinism.
http://medcitynews.com/2014/09/xeris-developing-glucagon-product-diabetes-control-raises-7-2m/